Hepatitis C virus

Phase I

This study is ongoing, but not recruiting participants.

The purpose of this study is to evaluate the safety, tolerability and immunogenicity of VGX-6150 as a second-line therapy in chronic hepatitis C patients.

Phase I Trial to Evaluate the Safety, Tolerability and Immunogenicity of VGX-6150 for Second-line Therapy of Chronic Hepatitis C Infection (VGX-6150-01).

VGX-6150-01

INO-8000/VGX-6150

For more information please go to the study protocol.



Hepatitis B virus

Phase I

This study is currently recruiting participants.

This study is an open-label study to evaluate the safety, tolerability, and immunogenicity of dose combinations of INO-1800 (DNA plasmids encoding HBsAg and HBcAg) and INO-9112 (DNA plasmid encoding human interleukin 12) delivered by electroporation (EP) in 126 (one hundred twenty six) entecavir or tenofovir treated HBeAg positive patients.

Phase I, Randomized, Open-Label, Active-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability & Immunogenicity of INO-1800 Alone or in Combination With INO-9112 Delivered IM Followed by EP in Select Nucleos(t)Ide Analogue-Treated, HBeAg+, Chronic Hepatitis B Patients.

HBV-001

INO-1800

For more information please go to the study protocol.

 


Ebola

Phase I

This study is ongoing, but not recruiting participants.

This study evaluates whether INO-4212 and its components INO-4201 and INO-4202 administered intramuscularly (IM) or intradermally (ID) followed by electroporation (EP) will be tolerated and immunogenic.

Phase 1, Open-Label Study to Evaluate the Safety, Tolerability, and Immunogenicity of INO-4212 and Its Components, INO-4201 and INO-4202, Given With or Without INO-9012, Administered IM or ID Followed by Electroporation in Healthy Volunteers.

EBOV-001

INO-4212

For more information please go to the study protocol.

 


HIV, providing coverage against global HIV clades

Phase I

This study is currently recruiting participants.

The purpose of this study is to evaluate the safety and tolerability of the PENNVAX®-GP HIV-1 DNA vaccine with or without interleukin 12 (IL-12) DNA adjuvant, given by intradermal or intramuscular injection with electroporation, in healthy, HIV-uninfected adults. The trial will measure immune responses following administration of the vaccine, which targets two env antigens as well as gag and pol antigens—providing global coverage against HIV-1 subtypes— in four groups of healthy subjects.

Evaluating the Safety and Immunogenicity of PENNVAX®-GP DNA Vaccine and IL-12 Plasmid, Delivered Via Intradermal or Intramuscular Electroporation in Healthy, HIV-Uninfected Adults.

HVTN 098, 11890

PENNVAX®-GP

For more information please go to the study protocol.

 


HIV, clades A, C, and D

Phase I

This study has been completed.

The purpose of this study is to evaluate the safety of and immune response to a primate vaccination with a synthetic DNA vaccine for the HIV subtypes A,C and D followed by a boost with a viral vector based HIV vaccine.

A Study of the Safety and Immunogenicity of PENNVAX®-G DNA (Env & Gag) Administered by Intramuscular Biojector 2000 or CELLECTRA® Intramuscular Electroporation Device Followed by MVA-CMDR (HIV-1 CM235 Env/CM240 Gag/Pol) Boost in Healthy, HIV Uninfected Adults

RV 262

PENNVAX®-G

For more information please go to the study protocol.


Middle East respiratory syndrome (MERS)

Phase I

This study is currently recruiting participants.

The Middle East Respiratory Syndrome Coronavirus (MERS CoV), a virus related to Severe Acute respiratory syndrome coronavirus (SARS CoV), was first recognized as a cause of severe pulmonary infection in 2012. Infection with MERS CoV has been diagnosed in more than 1600 individuals with a mortality rate between 35% and 40%. GLS-5300 is a DNA plasmid vaccine that expresses the MERS CoV spike (S) glycoprotein. This study will evaluate the safety of GLS-5300 at one of three dose levels following a three-injection vaccination regimen followed by electroporation. The study will also assess immune responses over a 1 year period with respect to the generation of antibody and cellular responses.

Phase I, Open-label, Dose Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5300, Administered IM Followed by Electroporation in Healthy Volunteers

NCT02670187

GLS-5300

For more information please go to the study protocol.


Zika virus

Phase I

This study is currently recruiting participants.

The clinical trial will assess the safety, tolerability, and immunogenicity of GLS-5700. GLS-5700 is a synthetic DNA plasmid vaccine against the Zika virus. ZIKA-001 is the first in man clinical trial of this vaccine which encodes for the premembrane-membrane and envelope regions of Zika virus.

Zika virus, first discovered in the Zika forest in 1947, has caused a large epidemic in South America, Central America, and the Caribbean islands commencing in late 2014 or early 2015. Zika virus can cause significant neurologic disease to include Guillain Barre Syndrome in adults and microcephaly and other birth defects among children born to mothers who are infected during pregnancy. At present no vaccines or treatments have been approved for Zika virus infection.

Phase I, Open-label, Dose-Ranging Study to Evaluate the Safety, Tolerability, and Immunogenicity of GLS-5700 Administered ID Followed by EP in Dengue Virus-Naïve Adults

NCT02809443

GLS-5700

For more information please go to the study protocol.